Please login to the form below

Not currently logged in
Email:
Password:

TEVA's tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives
TEVA

TEVA's tardive dyskinesia drug, SD-809 has been granted breakthrough therapy designation by the FDA.

The designation comes on the back of data from the phase II/III Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD) study which enrolled 117 patients with moderate to severe degrees of the condition.

Michael Hayden, president of global R&D and chief scientific officer at TEVA, said: “The granting of breakthrough therapy designation by the FDA represents significant progress toward advancing the clinical program for SD-809, as a potential, much-needed treatment option for the underserved tardive dyskinesia patient population.

“We remain excited about studying this innovative compound across a number of indications.”

Tardive dyskinesia is a condition characterised repetitive and uncontrollable movements of the tongue, lips, face and extremities and has been associated with the use of anti-psychotic drugs.

The condition affects around 500,000 people in the United States.

Breakthrough Therapy Designation is granted to a drug that is intended to treat a serious condition and preliminary clinical evidence suggests that SD-809 (deutetrabenazine) may demonstrate substantial improvement over available therapy. 

Article by
Nikhil Patel

10th November 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics